FdaApplication
ANDA 212199
Identifiers
- fda_app_no: ANDA212199
Properties
| Property | Value |
|---|---|
| applicant_name | SCIEGEN PHARMACEUTICALS INC |
| application_type | ANDA |
| approval_date | 2019-10-30 |
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| NAPROXEN SODIUM | NAPROXEN SODIUM | EQ 250MG BASE | TABLET;ORAL |
| NAPROXEN SODIUM | NAPROXEN SODIUM | EQ 500MG BASE | TABLET;ORAL |
2 products